The Ensign Group, Inc.
ENSG
$168.92
-0.59%
The Ensign Group, Inc. is a post-acute healthcare services provider in the United States, operating skilled nursing, assisted living, home health, hospice, mobile ancillary, and urgent care facilities through regional subsidiaries. It distinguishes itself as a leading operator in the fragmented skilled nursing industry, leveraging a decentralized management model and a captive REIT (Standard Bearer) to optimize property ownership and operational efficiency. The current investor narrative centers on Ensign's consistent revenue growth driven by demographic tailwinds and its ability to expand margins through operational improvements, though recent stock price volatility reflects concerns about regulatory changes in Medicare/Medicaid reimbursement and rising labor costs.…
ENSG
The Ensign Group, Inc.
$168.92
Investment Opinion: Should I buy ENSG Today?
Rating: Hold. Ensign Group is a well-run operator in a growing industry, but the stock's recent underperformance and regulatory risks warrant caution. The analyst consensus is bullish (Outperform/Overweight/Buy) with an average target of ~$184, implying ~9% upside.
Supporting Evidence: Revenue grew 20.17% YoY, TTM free cash flow is $370.71M, operating margin improved to 9.10%, and forward PE of 20.19x is below the 5-year average. The company is profitable with a trailing PE of 29.03x, which is a premium to the industry median of ~22x but justified by superior growth.
Risks & Conditions: The Hold rating could upgrade to Buy if the stock breaks above its 52-week high of $218, or if forward PE compresses below 18x. It would downgrade to Sell if revenue growth decelerates below 10% or if debt-to-equity rises above 2.5. Overall, the stock appears fairly valued relative to its history and peers, with limited upside from current levels.
Sign up to view all
ENSG 12-Month Price Forecast
Ensign Group's fundamentals are solid, with strong revenue growth and cash flow, but the stock's recent price action and relative weakness suggest caution. The base case of modest upside to ~$184 is most likely, but the risk/reward is balanced given the regulatory overhang. A bullish stance would require evidence of margin expansion and a catalyst to reverse the negative momentum, while a bearish stance would materialize if growth decelerates or regulatory headwinds intensify.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on The Ensign Group, Inc.'s 12-month outlook, with a consensus price target around $219.60 and implied upside of +30.0% versus the current price.
Average Target
$219.60
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$135 - $220
Analyst target range
Only 3 analysts cover Ensign, which is limited for a mid-cap stock. The consensus recommendation leans bullish, with ratings including Outperform (RBC Capital), Overweight (Stephens & Co.), and Buy (UBS), while Truist Securities maintains a Hold. The average estimated EPS is $9.13, with a range of $8.30 to $9.63, and average revenue estimate of $7.04 billion. Based on the current price of $168.22 and the average EPS estimate, the forward PE of 20.19x implies an average target price of approximately $184 (using 20.19x * $9.13), suggesting about +9% upside. However, the limited coverage means the consensus may not fully reflect market sentiment. The high EPS estimate of $9.63 implies a target of $194, while the low of $8.30 implies $168, near the current price. The narrow EPS range suggests relatively high conviction among analysts. Institutional ratings show no recent changes, with RBC Capital and Truist maintaining their stances since early 2026. The limited analyst coverage (3 analysts) is typical for a mid-cap stock and can lead to higher volatility and less efficient price discovery, but the bullish consensus indicates confidence in the company's growth story.
Drowning in data?
Find the real signal!
Bulls vs Bears: ENSG Investment Factors
Ensign Group presents a mixed picture: strong revenue growth (20.17% YoY) and robust free cash flow ($370.71M TTM) support the bull case, while significant underperformance versus the market (-28% relative to SPY over 3 months) and high debt (D/E 1.86) are key concerns. The bull case currently has stronger evidence given the company's consistent operational execution and attractive forward PE (20.19x), but the bear case hinges on whether the stock can reverse its relative weakness. The single most important tension is whether Ensign's fundamental growth can overcome the negative momentum and regulatory overhang to drive a re-rating.
Bullish
- Strong Revenue Growth Trajectory: Revenue grew 20.17% YoY in Q4 2025 to $1.361 billion, with accelerating sequential growth from $1.173 billion in Q1 2025. This outpaces the industry average and reflects demographic tailwinds from an aging population.
- Robust Free Cash Flow Generation: TTM free cash flow reached $370.71 million, up from $52.30 million in Q4 2024. This provides ample capacity for acquisitions and internal investments, supporting future growth.
- Attractive Forward Valuation: Forward PE of 20.19x implies a 44% earnings growth expectation, which is aggressive but supported by the company's track record. The trailing PE of 29.03x is below the 5-year average of ~28x, suggesting fair valuation relative to history.
- Consistent Margin Improvement: Operating margin improved to 9.10% in Q4 2025 from 8.90% in Q4 2024, while net margin remained stable at ~7%. This demonstrates operational efficiency and cost control despite inflationary pressures.
Bearish
- Significant Underperformance vs Market: The stock has underperformed SPY by 28% over the past 3 months and 6.13% over the past year. This persistent relative weakness suggests negative sentiment and potential structural headwinds.
- High Debt-to-Equity Ratio: Debt-to-equity of 1.86 is elevated, reflecting the REIT structure but increasing financial risk. Interest expense of $1.96 million in Q4 2025 could pressure earnings if rates remain high.
- Limited Analyst Coverage: Only 3 analysts cover the stock, which can lead to higher volatility and less efficient price discovery. The narrow coverage may also indicate lower institutional interest.
- Regulatory and Reimbursement Risk: Medicare and Medicaid programs contribute the majority of revenue. Changes in reimbursement policies or regulatory scrutiny could compress margins, as seen in the industry historically.
ENSG Technical Analysis
The stock is in a clear downtrend from its 52-week high of $218.00, currently trading at $168.22, which is 77.2% of its 52-week range (from low of $134.79). The 1-year price change of +12.97% masks a significant pullback from the highs, indicating that while the long-term trend is positive, the stock has lost substantial momentum. The current price near the midpoint of the range suggests indecision, with potential support at the 52-week low and resistance at the high. Over the past 3 months, the stock has declined 14.44%, while the 1-month change is +1.52%, showing a short-term bounce from the June lows. This divergence—negative 3-month but positive 1-month—could signal a potential short-term reversal or mean reversion, but the 6-month change of -3.28% confirms the broader weakness. The relative strength versus SPY is negative across all periods (1-year -6.13%, 3-month -28.00%), indicating significant underperformance. The 52-week low of $134.79 provides key support; a break below would signal further downside, while a move above the 52-week high of $218.00 would indicate a resumption of the uptrend. Beta of 0.689 suggests the stock is less volatile than the market, meaning it may not participate fully in market rallies but could offer downside protection during selloffs. The short ratio of 3.43 days indicates moderate short interest, which could fuel a short squeeze if positive catalysts emerge.
Beta
0.69
0.69x market volatility
Max Drawdown
-31.8%
Largest decline past year
52-Week Range
$135-$218
Price range past year
Annual Return
+15.1%
Cumulative gain past year
| Period | ENSG Return | S&P 500 |
|---|---|---|
| 1m | +8.8% | +2.0% |
| 3m | -15.1% | +10.6% |
| 6m | -2.8% | +8.3% |
| 1y | +15.1% | +20.4% |
| ytd | -2.9% | +10.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ENSG Fundamental Analysis
Revenue has grown consistently, with Q4 2025 revenue of $1.361 billion representing a 20.17% YoY increase from $1.132 billion in Q4 2024. The trailing twelve-month revenue run-rate is approximately $5.06 billion, with sequential growth from $1.173 billion in Q1 2025 to $1.361 billion in Q4 2025, indicating accelerating momentum. The Skilled Services segment generated $2.425 billion in revenue, while the Standard Bearer segment contributed $62.85 million, highlighting the core business's dominance. This growth trajectory supports the investment case as Ensign benefits from an aging population and increased demand for post-acute care. Net income for Q4 2025 was $95.45 million, up from $79.69 million in Q4 2024, reflecting improved profitability. Gross margin improved to 8.67% in Q4 2025 from 15.80% in Q4 2024, but this is due to a change in revenue recognition (cost of revenue includes pass-through costs); operating margin was 9.10% in Q4 2025 versus 8.90% in Q4 2024, showing stable operational efficiency. Net margin was 7.02% in Q4 2025, up from 7.04% in Q4 2024, indicating consistent profitability. The company is profitable with a trailing PE of 29.03, and margins are stable, which is typical for the skilled nursing industry. Free cash flow for Q4 2025 was $133.48 million, up from $52.30 million in Q4 2024, demonstrating strong cash generation. The debt-to-equity ratio of 1.86 is elevated but manageable given the REIT structure, and the current ratio of 1.42 indicates adequate liquidity. ROE of 15.41% is solid, reflecting efficient use of equity. The company generated $370.71 million in TTM free cash flow, providing ample capacity for internal growth investments and acquisitions.
Quarterly Revenue
$1.4B
2025-12
Revenue YoY Growth
+20.17%
YoY Comparison
Gross Margin
8.67%
Latest Quarter
Free Cash Flow
$370713000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ENSG Overvalued?
Since net income is positive, the primary valuation metric is the PE ratio. The trailing PE is 29.03x, while the forward PE is 20.19x, implying the market expects significant earnings growth. The gap between trailing and forward PE suggests analysts anticipate a 44% increase in earnings per share over the next year, which is aggressive but supported by the company's growth trajectory. The PS ratio of 1.97x provides a secondary check. Compared to the industry average (Medical Care Facilities), Ensign's trailing PE of 29.03x is at a premium to the sector median of approximately 22x (based on industry data), representing a 32% premium. This premium is justified by Ensign's superior revenue growth (20% YoY) and consistent margin expansion, as well as its competitive position as a leading skilled nursing operator. Historically, Ensign's trailing PE has ranged from 17.48x (Q2 2022) to 72.53x (Q4 2023), with the current 29.03x near the lower end of the 5-year range. The current PE is below the 5-year average of approximately 28x, suggesting the stock is not overvalued relative to its own history. The PB ratio of 4.47x is also near the historical average, indicating fair valuation.
PE
29.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 17x~73x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
24.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Ensign's debt-to-equity ratio of 1.86 is elevated, increasing vulnerability to rising interest rates. Interest expense of $1.96 million in Q4 2025, while manageable, could grow if the company takes on more debt for acquisitions. The company's reliance on Medicare/Medicaid reimbursement (majority of revenue) exposes it to policy changes that could compress margins. Free cash flow of $370.71M TTM is strong, but any disruption in cash generation could strain the balance sheet.
Market & Competitive Risks: The stock has underperformed SPY by 28% over the past 3 months, indicating negative sentiment. With a beta of 0.689, it is less volatile than the market, but this also means it may not participate fully in rallies. The skilled nursing industry is fragmented and competitive; Ensign's decentralized model is a differentiator, but competitors could replicate it. Limited analyst coverage (3 analysts) reduces visibility and could lead to sharp price moves on news.
Worst-Case Scenario: A combination of Medicare reimbursement cuts, rising labor costs, and a recession could pressure margins and lead to earnings misses. The 52-week low of $134.79 represents a 19.9% downside from the current price of $168.22. In a severe downturn, the stock could test that level, resulting in a loss of approximately 20% for investors buying at current levels.
FAQ
The primary risks are regulatory (Medicare/Medicaid reimbursement changes), financial (high debt-to-equity of 1.86), and competitive (fragmented industry with low barriers). Additionally, the stock has shown significant underperformance versus the market (28% relative decline over 3 months), indicating negative sentiment. Labor cost inflation could also pressure margins. The most severe risk is a combination of reimbursement cuts and rising costs leading to earnings misses, potentially driving the stock to its 52-week low of $134.79.
The 12-month outlook is balanced: a base case (50% probability) sees the stock trading between $168 and $194, with an average target of ~$184. A bull case (25% probability) targets $194-$218, driven by strong earnings and a re-rating. A bear case (25% probability) sees the stock falling to $135-$168, pressured by regulatory or operational headwinds. The most likely scenario is modest upside, but the stock's recent momentum is negative, so investors should monitor catalysts closely.
Ensign's trailing PE of 29.03x is a premium to the industry median of ~22x, reflecting its superior growth. However, the forward PE of 20.19x is below the 5-year average of ~28x, suggesting the stock is not overvalued relative to its own history. The PS ratio of 1.97x is also reasonable. The valuation implies the market expects significant earnings growth (44% over the next year), which is aggressive but supported by the company's track record. Overall, ENSG appears fairly valued given its growth profile.
Ensign Group offers a compelling growth story with 20.17% YoY revenue growth and strong free cash flow of $370.71M TTM. However, the stock has underperformed the market significantly (down 28% relative to SPY over 3 months) and trades at a forward PE of 20.19x, which is reasonable but not cheap. The analyst consensus is bullish with an average target of ~$184, implying ~9% upside. For long-term investors with a high risk tolerance, it could be a good buy on dips, but near-term headwinds suggest waiting for a better entry point near support levels.
Ensign Group is better suited for long-term investment given its consistent growth and demographic tailwinds. The stock's beta of 0.689 indicates lower volatility, making it less attractive for short-term trading. The dividend yield is minimal (0.14%), so income-seeking investors should look elsewhere. A minimum holding period of 3-5 years is recommended to allow the company's growth story to play out and to ride out regulatory cycles. Short-term traders may find the stock range-bound between $135 and $218.
